SC 13G: TherapeuticsMD, Inc.

AI Summary

SC 13G filing by TherapeuticsMD, Inc..

Risk Assessment

Risk Level: low

Filing Documents

• txmd.htm (SC 13G) — 61KB
• 0001600136-24-000007.txt ( ) — 63KB

Ownership***

Item 4. Ownership*** As of the close of business on September 30, 2024, Clearline Capital LP, Clearline Capital LLC and Marc Majzner beneficially owned 636,622 shares, or 5.52%, of the Issuer’s Common Stock outstanding. The percentage was calculated based on the 11,532,432 total shares of Common Stock outstanding as of September 30, 2024, as per the Issuer’s Form 10-Q dated August 12, 2024. (a) Amount Beneficially Owned***: As of the close of business on September 30, 2024, Clearline Capital LP, a Delaware limited partnership, beneficially owned 636,622 shares of the Issuer’s Common Stock. As of the close of business on September 30, 2024, Clearline Capital LLC, a Delaware limited liability company, beneficially owned 636,622 shares of the Issuer’s Common Stock. As of the close of business on September 30, 2024, Marc Majzner, beneficially owned 636,622 shares of the Issuer’s Common Stock. (b) Percent of Class: As of the close of business on September 30, 2024, Clearline Capital LP beneficially owned 5.52% of the Issuer’s Common Stock outstanding. As of the close of business on September 30, 2024, Clearline Capital LLC beneficially owned 5.52% of the Issuer’s Common Stock outstanding. As of the close of business on September 30, 2024, Marc Majzner beneficially owned 5.52%, of the Issuer’s Common Stock outstanding. (c) Number of shares as to which such person has: (i) Sole power to vote or to direct the vote: 0 (ii) Shared power to vote or to direct the vote: Clearline Capital LP beneficially owned 636,622 shares as of close of business on September 30, 2024 Clearline Capital LLC beneficially owned 636,622 shares as of close of business on September 30, 2024 Marc Majzner beneficially owned 636,622 shares as of close of business on September 30, 2024 (iii) Sole power to dispose or to direct the disposition of: 0 (iv) Shared power to dispose or to direct the disposition of: Clearline Capital LP be

Ownership of Five Percent or Less of a Class

Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

Ownership of more than Five Percent on Behalf of Another Person. Not Applicable

Item 6. Ownership of more than Five Percent on Behalf of Another Person. Not Applicable

Identification and classification of the subsidiary which acquired the security being reported on by

Item 7. Identification and classification of the subsidiary which acquired the security being reported on by the parent holding company or control person. Not Applicable

Identification and classification of members of the group. Not Applicable

Item 8. Identification and classification of members of the group. Not Applicable

Notice of Dissolution of Group. Not Applicable

Item 9. Notice of Dissolution of Group. Not Applicable

Certifications

Item 10. Certifications. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: November 12, 2024 CLEARLINE CAPITAL LP By: Clearline Capital LLC By: /s/Marc Majzner ___ Name: Marc Majzner Title: Managing Member CLEARLINE CAPITAL LLC By: /s/Marc Majzner ___ Name: Marc Majzner Title: Managing Member MARC MAJZNER /s/Marc Majzner ___ The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of this filing person), evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature. Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001). Exhibit 1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of November 12, 2024, is by and among Clearline Capital LP, Clearline Capital LLC and Marc Majzner (collectively, the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commission a statement on Schedule 13D and/or 13G with respect to shares of Common Stock of TherapeuticsMD, Inc. beneficially owned by them from time to time. Pursuant to and in accordance with Rule 13(d)(1)(k) promulgated under the Securities Exchange Act of 1934, as amended, the Filers hereby agree to file a single statement on Schedule 13D and/or 13G (and any amendments thereto) on behalf of each of the Filers, and hereby further agree to file this

View Full Filing

View this SC 13G filing on SEC EDGAR